Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560803 | 1.00 | RAB9A (0.55) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL16224346 | 0.85 | KMT2A (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL17560854 | 0.85 | KMT2A (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL17560933 | 0.82 | SMN1; SMN2 (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL16224305 | 0.82 | SMN1; SMN2 (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL16224345 | 0.82 | MAPT (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL16224338 | 0.82 | SMN1; SMN2 (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL17560833 | 0.82 | MAPT (0.57) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL16212197 | 0.82 | SMN1; SMN2 (0.64) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL16212199 | 0.82 | SMN1; SMN2 (0.64) | RAB9ANPC1MAPTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566012-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD (AU) | 2023-01-31 | — | — | US | claimed |
| US-20210009552-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2021-01-14 | — | — | US | claimed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| EP-3188722-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | Neoculi Pty Ltd (AU) | 2017-07-12 | — | — | EP | claimed |
| WO-2016033635-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2016-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566012-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | RAB9A 3198/4885NPC1 282/4885MAPT 3694/4885 |
| US-20210009552-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | RAB9A 3198/4885NPC1 282/4885MAPT 3694/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | RAB9A 3198/4885NPC1 282/4885MAPT 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.